Boston Scientific wins FDA approval for implantable heart devices
Three new product lines include implantable cardioverter defibrillators
|
Tweet
|
The Lowell Sun
 | Interested in AEDs? Get pricing, product info & discounts from top companies. | ||||||||||||||
| |||||||||||||||
NATICK — Boston Scientific Inc. said yesterday that the Food and Drug Administration approved several new implantable heart devices the company developed.
The company said the FDA approved devices that will be marketed under the names Incepta, Energen and Punctua devices.
All three product lines include implantable cardioverter defibrillators, which are used to treat rapid heartbeats, and cardiac resynchronization devices, which include an ICD and a resynchronization device used to coordinate the pumping of the heart.
The company said the devices are easier to implant and less visible from the outside than older devices.
Copyright 2011 MediaNews Group, Inc.
|
All Rights Reserved
Comments
The comments below are member-generated and do not necessarily reflect the opinions of EMS1.com or its staff.
No comments
